AN EVOLVING VACCINES PORTFOLIO THAT ADDRESSES GLOBAL HEALTH RISKS
AND UNMET NEEDS

As The World Moves Faster, So Should We

 

Climate change, urbanization, and international travel contribute to the risk of infectious diseases globally.1 At Bavarian Nordic, we are driven to find vaccine solutions to help combat the threat of infectious diseases.

 

Committed to Helping Save and Improve Lives

 

about-commit-1

Providing disease awareness and education

about-commit-2

Expanding production capabilities to ensure reliable manufacturing and supply of vaccines

about-commit-3

Applying our innovative spirit to continue leadership in infectious diseases and travel health

about-commit-4

Being a trusted partner for your vaccine needs

 
Building on a Legacy of Vaccine Achievements

 

Ellipse 5-0

1994

Founded in Denmark

Ellipse 5-1

2007

First smallpox supply contract with US Government 

Ellipse 5-2

2014

Entered collaboration with Janssen for development and supply of Ebola vaccine

Ellipse 5-3

2019

Approval in the United States for Smallpox and Monkeypox Vaccine, Live, Non-replicating suspension for subcutaneous injection 

Ellipse 5-4

2020

US Commercial team established; acquisition of Rabies Vaccine

Ellipse 5-5

2023

Acquisition of Typhoid Vaccine Live Oral Ty21a, Cholera Vaccine Live Oral, and a Phase 3 vaccine candidate for the prevention of chikungunya virus from Emergent BioSolutions

 

With pride in our achievements in vaccine development over the past 30 years, we are focused on the future. Right now, we are working on bringing patients around the globe an even greater degree of protection from infectious diseases.

 

An Evolving Vaccines Portfolio That Addresses Global Health Risks and Unmet Needs

 

about-vaccines-1

RABIES2,3

Found on all continents, except Antarctica Causes ~59,000 deaths globally each year and is nearly 100% fatal once clinical symptoms appear

about-vaccines-2

TYPHOID5

~11–21 million cases of typhoid fever occur worldwide each year, with ~85% of cases in the US occurring among international travelers 
~135,000–230,000 deaths are attributed to typhoid and paratyphoid fever worldwide each year 

about-vaccines-3

MPOX4

>90,000 cases have been reported globally since the start of the 2022-2023 outbreak >150 deaths have been reported globally since the start of the 2022-2023 outbreak 

about-vaccines-4

CHOLERA6

~1.3–4.0 million cases of cholera occur worldwide each year 
Up to 143,000 deaths are attributed to cholera worldwide each year 

  1. Semenza JC, Rocklöv J, Ebi KL. Climate change and cascading risks from infectious disease. Infect Dis Ther. 2022;11(4):1371-1390.
  2. CDC Yellow Book 2024: Rabies. Accessed March, 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/rabies
  3. Rao AK, Briggs D, Moore SM, et al. Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(18):619-627.
  4. World Health Organization. 2022-23 Mpox (Monkeypox) outbreak: global trends. Accessed March, 2024. https://worldhealthorg.shinyapps.io/mpx_global/
  5. CDC Yellow Book 2024: Typhoid & paratyphoid fever. Accessed March, 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever

  6. World Health Organization. Cholera Fact Sheet. Accessed March, 2024. https://www.who.int/news-room/fact-sheets/detail/cholera